FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Abnormal activation of epidermal growth factor receptor (EGFR) drives non-small cell lung cancer (NSCLC) development. EGFR mutations-mediated resistance to tyrosine-kinase inhibitors (TKIs) is a major hurdle for NSCLC treatment. Here, we show that F-box protein FBXL2 targets EGFR and EGFR TKI-resistant mutants for proteasome-mediated degradation, resulting in suppression of EGFR-driven NSCLC growth. Reduced FBXL2 expression is associated with poor clinical outcomes of NSCLC patients. Furthermore, we show that glucose-regulated protein 94 (Grp94) protects EGFR from degradation via blockage of FBXL2 binding to EGFR. Moreover, we have identified nebivolol, a clinically used small molecule inhibitor, that can upregulate FBXL2 expression to inhibit EGFR-driven NSCLC growth. Nebivolol in combination with osimertinib or Grp94-inhibitor-1 exhibits strong inhibitory effects on osimertinib-resistant NSCLC. Together, this study demonstrates that the FBXL2-Grp94-EGFR axis plays a critical role in NSCLC development and suggests that targeting FBXL2-Grp94 to destabilize EGFR may represent a putative therapeutic strategy for TKI-resistant NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
Self-citationThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
HSP90 at the hub of protein homeostasis: emerging mechanistic insights
Taipale, M., Jarosz, D. F., & Lindquist, S. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2918 · Cited by 1,818
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Structure of the Cul1–Rbx1–Skp1–F boxSkp2 SCF ubiquitin ligase complex
Zheng, N., Schulman, B. A., Song, L., Miller, J. J., Jeffrey, P. D., Wang, P., Chu, C., Koepp, D. M., Elledge, S. J., Pagano, M., et al. (2002) · Nature · doi:10.1038/416703a · Cited by 1,507
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Ercan, D., Choi, H. G., Yun, C.-H., Capelletti, M., Xie, T., Eck, M. J., Gray, N. S., & Jänne, P. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2789 · Cited by 368
Conformational dynamics of the molecular chaperone Hsp90
Krukenberg, K. A., Street, T. O., Lavery, L. A., & Agard, D. A. (2011) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583510000314 · Cited by 308
PTEN Counteracts FBXL2 to Promote IP3R3- and Ca2+-Mediated Apoptosis Limiting Tumour Growth
Kuchay, S., Giorgi, C., Simoneschi, D., Pagan, J., Missiroli, S., Saraf, A., Florens, L., Washburn, M. P., Collazo-Lorduy, A., Castillo-Martin, M., et al. (2017) · Nature · doi:10.1038/nature22965 · Cited by 251
Cited by
Lei, Y., Liao, F., Tian, Y., Wang, Y., Xia, F., & Wang, J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1321176 · Cited by 35
“Decreasing the expression of ELK1, C-FOS, NF-κ B (Kawahara et al., 2016; Nagata et al., 2020) α 1a-AR Silodosin Glioma, OSCC Upregulation of Autophagy (Liu B. et al., 2021; Liu Z. et al., 2021; Xing et al., 2023) α 1a-AR Doxazosin PCa, AML, Inhibiting the PI3K/Akt/mTOR pathway (Li et al., 2020; Sun et al., 2020; Liu D…”
BackgroundStructural transitions modulate the chaperone activities of Grp94
Amankwah, Y. S., Fleifil, Y., Unruh, E., Collins, P., Wang, Y., Vitou, K., Bates, A., Obaseki, I., Sugoor, M., Alao, J. P., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2309326121 · Cited by 22
“In the case of Grp94, such stable interactions stabilize and protect the bound clients from degradation, which can alter proteome - wide interaction networks (74, 75).”
Self-citationXu, Y., Li, X., Cheng, F., Zhao, B., Fang, M., Li, Z., & Meng, S. (2024) · Nature Communications · doi:10.1038/s41467-024-45426-5 · Cited by 7
Self-citation
Metadata
- Authors
- Niu, M., Xu, J., Liu, Y., Li, Y., He, T., Ding, L., He, Y., Yi, Y., Li, F., Guo, R., Gao, Y., Li, R., Li, L., Fu, M., Hu, Q., Luo, Y., Zhang, C., Qin, K., Yi, J., Yu, S., Yang, J., Chen, H., Wang, L., Li, Z., Dong, B., Qi, S., Ouyang, L., Zhang, Y., Cao, Y., & Xiao, Z.-X. J.
- Venue
- Nature Communications
- Published
- 2021-10-11
- Volume
- 12
- Issue
- 1
- Pages
- 5919-5919
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W3205685501
- Cited by
- 59
- References
- 9
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth. https://app.cochat.ai/papers/10.1038/s41467-021-26222-x
- The paper
- Niu, M., Xu, J., Liu, Y., Li, Y., He, T., Ding, L., He, Y., Yi, Y., Li, F., Guo, R., Gao, Y., Li, R., Li, L., Fu, M., Hu, Q., Luo, Y., Zhang, C., Qin, K., Yi, J., . . . Xiao, Z.-X. J. (2021). FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth. Nature Communications. https://doi.org/10.1038/s41467-021-26222-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.